CD388: A universally protective Drug-Fc Conjugate that targets influenza virus neuraminidase
Simon Döhrmann(Cidara Therapeutics (United States)), Leslie W. Tari(Arcturus Therapeutics (United States)), Wanlong Jiang(Cidara Therapeutics (United States)), Joanna Donatelli(University of California, San Francisco), Allen Borchardt(Cidara Therapeutics (United States)), Nicholas Dedeic(Cidara Therapeutics (United States)), Thanh Lam(Arcturus Therapeutics (United States)), Elizabeth Abelovski(Cidara Therapeutics (United States)), Grayson Hough(Arcturus Therapeutics (United States)), Travis J. Haussener(Cidara Therapeutics (United States)), Jason N. Cole(Cidara Therapeutics (United States)), Karin Amundson(Cidara Therapeutics (United States)), Amanda Almaguer(Cidara Therapeutics (United States)), Daniel C. Bensen(State Street (United States)), Alain Noncovich(Cidara Therapeutics (United States)), Voon Ong(Arcturus Therapeutics (United States)), Joanne Fortier(Cidara Therapeutics (United States)), Zhiyong Chen(Hunan University), Rajvir Grewal(Cidara Therapeutics (United States)), Jeffrey L. Stein(Cidara Therapeutics (United States)), D. Zuill(Cidara Therapeutics (United States)), Thomas P. Brady(Cidara Therapeutics (United States)), James M. Balkovec(Cidara Therapeutics (United States)), James Levin(Cidara Therapeutics (United States)), Jeffrey B. Locke(Cidara Therapeutics (United States))
Cited by 0
Related Papers
Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms
|Cell Reports|2021|266
Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations
|Cells|2021|187
Comparative Genomic Analysis of Archaeal Genotypic Variants in a Single Population and in Two Different Oceanic Provinces
|Applied and Environmental Microbiology|2002|171
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay
|Science Advances|2021|150